Annual report
2413.TEDINET S100YJ25
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥351.4bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥284.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥238.9bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥73.5bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥63.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥76.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥64.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥68.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥49.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥45.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥54.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥44.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥637.4bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥581.7bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥490.8bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥400.6bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥346.0bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥190.7bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥168.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥446.6bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥412.8bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥408.2bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥378.4bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥351.9bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥302.6bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥257.8bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥156.2bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥134.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥104.3bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥70.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥58.3bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥15.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.5bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥35.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥27.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥9.4bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥72.53 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.62 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.68 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.5 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.6 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥66.63 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥608.98 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥555.07 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥516.49 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 64.0% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.1% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.5% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.8% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 17,010 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 15,360 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,100 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 10,533 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥47.2bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥45.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥51.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥19.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥27.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥84.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥31.9bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥27.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥24.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥21.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥75.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥268.7bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥265.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥251.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥232.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥45.4bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥31.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥223.3bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥233.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥226.0bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥162.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥152.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥79.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥78.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥35.44 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.85 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥35.43 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.77 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥332.42 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥341.34 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥331.17 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 82.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.4% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 679,120,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,077,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,063,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 750 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 704 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 649 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 588 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 68
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| Career Solutionreportable segment | employees | at 2026-03-31 | 1061 pure |
| Career Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥22.8bn |
| Career Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥22.7bn |
| Career Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥75m |
| Career Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.9bn |
| Evidence Solutionreportable segment | employees | at 2026-03-31 | 2361 pure |
| Evidence Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥24.5bn |
| Evidence Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.4bn |
| Evidence Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥167m |
| Evidence Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 3407 pure |
| Medical Platformreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥107.8bn |
| Medical Platformreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥104.0bn |
| Medical Platformreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.8bn |
| Medical Platformreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥35.9bn |
| Overseasreportable segment | employees | at 2026-03-31 | 3065 pure |
| Overseasreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥16m |
| Overseasreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥14.9bn |
| Patient Solutionreportable segment | employees | at 2026-03-31 | 1208 pure |
| Patient Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| Patient Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Site Solutionreportable segment | employees | at 2026-03-31 | 5740 pure |
| Site Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥54.4bn |
| Site Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥54.3bn |
| Site Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7m |
| Site Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.8bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥353.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥349.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥70.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.1bn |
| Career Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥32m |
| Career Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Evidence Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥24.2bn |
| Evidence Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.0bn |
| Evidence Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥223m |
| Evidence Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Medical Platformreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medical Platformreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥88.2bn |
| Medical Platformreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Medical Platformreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥34.1bn |
| Overseasreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥80.6bn |
| Overseasreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥80.5bn |
| Overseasreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥64m |
| Overseasreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥14.7bn |
| Patient Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥824m |
| Site Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Site Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥286.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥282.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥65.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 658 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,852
| Item | Context | Value | Unit |
|---|---|---|---|
| Rent expenses sga IFRS | Prior1YearDuration | 696000000 | JPY |
| Rent expenses sga IFRS | CurrentYearDuration | 970000000 | JPY |
| Other sga IFRS | Prior1YearDuration | 18095000000 | JPY |
| Other sga IFRS | CurrentYearDuration | 22209000000 | JPY |
| Selling general and administrative expenses IFRS | Prior1YearDuration | 92946000000 | JPY |
| Selling general and administrative expenses IFRS | CurrentYearDuration | 105740000000 | JPY |
| Change in fair value of financial instruments measured at fair value other income IFRS | Prior1YearDuration | － | JPY |
| Change in fair value of financial instruments measured at fair value other income IFRS | CurrentYearDuration | 1521000000 | JPY |
| Gain on sale of investments in associates IFRS | Prior1YearDuration | 425000000 | JPY |
| Gain on sale of investments in associates IFRS | CurrentYearDuration | 4101000000 | JPY |
| Gain on sale of fixed assets IFRS | Prior1YearDuration | 138000000 | JPY |
| Gain on sale of fixed assets IFRS | CurrentYearDuration | 1451000000 | JPY |
| Miscellaneous income IFRS | Prior1YearDuration | 568000000 | JPY |
| Miscellaneous income IFRS | CurrentYearDuration | 660000000 | JPY |
| Other other income IFRS | Prior1YearDuration | 263000000 | JPY |
| Other other income IFRS | CurrentYearDuration | 395000000 | JPY |
| Other income IFRS | Prior1YearDuration | 1395000000 | JPY |
| Other income IFRS | CurrentYearDuration | 8127000000 | JPY |
| Impairment losses pl IFRS | Prior1YearDuration | 2077000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration | 6677000000 | JPY |
| Change in fair value of financial instruments measured at fair value other expenses IFRS | Prior1YearDuration | 253000000 | JPY |
| Change in fair value of financial instruments measured at fair value other expenses IFRS | CurrentYearDuration | － | JPY |
| Other other expenses IFRS | Prior1YearDuration | 185000000 | JPY |
| Other other expenses IFRS | CurrentYearDuration | 478000000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 2514000000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 7155000000 | JPY |
| Interest income IFRS | Prior1YearDuration | 2531000000 | JPY |
| Interest income IFRS | CurrentYearDuration | 2414000000 | JPY |
| Foreign exchange gain IFRS | Prior1YearDuration | － | JPY |
| Foreign exchange gain IFRS | CurrentYearDuration | 1327000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 2531000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 3741000000 | JPY |
| Financial liabilities measured at amortized cost interest expenses IFRS | Prior1YearDuration | 390000000 | JPY |
| Financial liabilities measured at amortized cost interest expenses IFRS | CurrentYearDuration | 577000000 | JPY |
| Lease obligations interest expenses IFRS | Prior1YearDuration | 304000000 | JPY |
| Lease obligations interest expenses IFRS | CurrentYearDuration | 433000000 | JPY |
| Other finance costs IFRS | Prior1YearDuration | 22000000 | JPY |
| Other finance costs IFRS | CurrentYearDuration | 2000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 717000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 1012000000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 78812000000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 79816000000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant_NonConsolidatedMember | 87000000 | JPY |
| Electronically recorded monetary claims operating ca | CurrentYearInstant_NonConsolidatedMember | 51000000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 10361000000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 9605000000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 39000000 | JPY |
| Work in process | CurrentYearInstant_NonConsolidatedMember | 45000000 | JPY |
| Supplies | Prior1YearInstant_NonConsolidatedMember | 509000000 | JPY |
| Supplies | CurrentYearInstant_NonConsolidatedMember | 496000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |